News

Alternative Anti-VEGF Treatment Regimens in Exudative Age-related Macular Degeneration Robert B Bhisitkul; Jay M Stewart Disclosures Expert Rev Ophthalmol. 2010;5 (6):799-809. 0 ...
Send comments and news tips to [email protected]. Cite this: Edited by Shrabasti Bhattacharya. Intensive Bevacizumab Boosts Vision in Macular Degeneration - Medscape - June 19, 2025.
Findings could help explain the links between macular degeneration and cardiovascular disease, which both worsen with age.
Ophthalmologist, talks about wet and dry macular degeneration. Donald Trump Makes Eye-Rolling New Title Suggestion For Pete Hegseth King Charles Has Switched Up the Plans for Donald Trump's State ...
Cochrane corner: artificial intelligence for diagnosing exudative age-related macular degeneration Ariel Yuhan Ong Henry David Jeffry Hogg Pearse A. Keane Editorial 20 Jan 2025 Eye Volume: 39, P ...
A new study from Washington University School of Medicine in St. Louis identifies a possible way to slow or block progression ...
Fixing problems with cholesterol metabolism might help slow or prevent a common cause of age-related vision loss, a new WashU ...
More information: Reut Shor et al, Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration, JAMA Ophthalmology (2025). DOI: 10.1001/jamaophthalmol.2025.1455 ...
Source Reference: Shor R, et al "Glucagon-like peptide-1 receptor agonists and risk of neovascular age-related macular degeneration" JAMA Ophthalmol 2025; DOI: 10.1001/jamaophthalmol.2025.1455.
A new study suggests that measuring specific immune system proteins in the blood could help predict which patients with intermediate age-related macular degeneration (AMD) are most likely to ...
Market is one of the leading causes of irreversible vision loss in individuals aged 50 and above. With the global aging population increasing rapidly, the burden of AMD is escalating, pushing the ...
Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants ...